Medivation (NASDAQ: MDVN) and Astellas Pharma Inc. announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE